Arterial hypertension in patients with heart failure

Heart Failure Clinics

Volumn 10, Issue 2, 2014, Pages 233-242

  Díez, Javier ^a,b,c  

^a Centre of Applied Medical Research   (Spain)

^b Department of Cardiology and Cardiac Surgery University Clinic ^*  (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Arterial hypertension; Ejection fraction; Heart failure; Left ventricular hypertrophy; Myocardial remodeling

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR MAGNETIC RESONANCE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; REVIEW; COMPLICATION; HYPERTROPHY, LEFT VENTRICULAR; PATHOLOGY; PATHOPHYSIOLOGY;

HEART FAILURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR;

EID: 84896385242     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2013.12.004     Document Type: Review

References (64)

1. Yusuf P.S., Hawken S., Ôunpuu S., et al. Effect ofpotentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
2. Frohlich E.D., Apstein C., Chobanian A.V., et al. The heart in hypertension. NEngl J Med 1992, 327:998-1008.
3. Agno F.S., Chinali M., Bella J.N., et al. Aortic valve sclerosis is associated with preclinical cardiovascular disease in hypertensive adults: the HyperGen study. JHypertens 2005, 23:867-873.
4. Kannel W.B. Incidence and epidemiology of heart failure. Heart Fail Rev 2000, 5:167-173.
5. Kenchaiah S., Narula J., Vasan R.S. Risk factors forheart failure. Med Clin North Am 2004, 88:1145-1172.
6. Mahmood S.S., Wang T.J. The epidemiology of congestive heart failure: the Framingham Heart Study perspective. Glob Heart 2013, 8:77-82.
7. Khatibzadeh S., Farzadfar F., Oliver J., et al. Worldwide risk factors for heart failure: a systematic review and pooled analysis. Int J Cardiol 2012, 168:1186-1194.
8. Tocci G., Sciarretta S., Volpe M. Development of heart failure in recent development trials. JHypertens 2008, 26:1477-1486.
9. Campbell R.T., Jhund P.S., Castagno D., et al. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?. JAm Coll Cardiol 2012, 60:2349-2356.
10. Ho J.E., Lyass A., Lee D.S., et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail 2013, 6:279-286.
11. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012, 33:1750-1757.
12. Meerson F.Z. Compensatory hyperfunction of the heart and cardiac insufficiency. Circ Res 1962, 10:250-258.
13. Drazner M.H. The progression of hypertensive heart disease. Circulation 2011, 123:327-334.
14. Giampietri C., Petrungaro S., Musumeci M., et al. c-Flip overexpression reduces cardiac hypertrophy in response to pressure overload. JHypertens 2008, 26:1008-1016.
15. Frohlich E.D., González A., Díez J. Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocyte hypertrophy. JHypertens 2010, 29:17-26.
16. Díez J., González A., López B., et al. Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2005, 2:209-216.
17. López B., Querejeta R., González A., et al. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. Hypertension 2012, 60:677-683.
18. López B., González A., Querejeta R., et al. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. JAm Coll Cardiol 2006, 48:89-96.
19. Yip G.W., Fung J.W., Tan Y.T., et al. Hypertension and heart failure: a dysfunction of systole, diastole or both?. JHum Hypertens 2009, 23:295-306.
20. Steeds R.P. Multimodality imaging in heart failure patients. Curr Opin Cardiol 2013, 28:209-215.
21. Pozzoli M., Traversi E., Cioffi G., et al. Loading manipulations improve the prognostic value of Doppler evaluation of mitral flow in patients with chronic heart failure. Circulation 1997, 95:1222-1230.
22. Giannuzzi P., Temporelli P.L., Bosimini E., et al. Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. JAm Coll Cardiol 1996, 28:383-390.
23. Ohtani T., Mohammed S.F., Yamamoto K., et al. Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. Eur Heart J 2012, 33:1742-1749.
24. Armstrong A.C., Gidding S., Gjesdal O., et al. LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. JACC Cardiovasc Imaging 2012, 5:837-848.
25. Piella G., De Craene M., Bijnens B.H., et al. Characterizing myocardial deformation in patients with left ventricular hypertrophy of different etiologies using the strain distribution obtained by magnetic resonance imaging. Rev Esp Cardiol 2010, 63:1281-1291.
26. Miller C.A., Naish J.H., Bishop P., et al. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging 2013, 6:373-383.
27. Schwitter J., DeMarco T., Kneifel S., et al. Magnetic resonance-based assessment of global coronary flow and flow reserve and its relation to left ventricular functional parameters: a comparison with positron emission tomography. Circulation 2000, 101:2696-2702.
28. Gluba A., Bielecka-Dabrowa A., Mikhailidis D.P., et al. An update on biomarkers of heart failure in hypertensive patients. JHypertens 2012, 30:1681-1689.
29. López B., González A., Querejeta R., et al. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. JHypertens 2009, 27:418-424.
30. Collier P., Watson C.J., Voon V., et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?. Eur J Heart Fail 2011, 13:1087-1095.
31. Querejeta R., López B., González A., et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004, 110:1263-1268.
32. Cheng J.M., Akkerhuis K.M., Battes L.C., et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail 2013, 15(12):1350-1362.
33. Georgiopoulou V.V., Kalogeropulos A.P., Butler J. Heart failure in hypertension. Prevention and treatment. Drugs 2012, 72:1373-1398.
34. Moser M., Hebert P.R. Prevention of disease prevention, left ventricular heart hypertrophy and congestive heart failure in hypertension treatment trials. JAm Coll Cardiol 1996, 27:1214-1218.
35. Sciarretta S., Palano F., Tocci G., et al. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med 2011, 171:384-394.
36. Muiesan M.L., Salvetti M., Rizzoni D., et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. JHypertens 1995, 13:1091-1095.
37. Schlaich M.P., Schmieder R.E. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. Am J Hypertens 1998, 11(11 Pt 1):1394-1404.
38. Whinnett Z.I., Davies J.E., Fontana M., et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart 2009, 95:56-62.
39. Lindenfeld J., Albert N.M., Boehmer J.P., et al. HFSA 2010 comprehensive heart failure practice guideline. JCard Fail 2010, 16:e1-e194.
40. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. NEngl J Med 1987, 316:1429-1435.
41. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. NEngl J Med 1991, 325:293-302.
42. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. NEngl J Med 1996, 334:1349-1355.
43. Brophy J.M., Joseph L., Rouleau J.L. Beta-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med 2001, 134:550-560.
44. Effectiveness of spironolactone added to an angiotensin converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996, 78:902-907.
45. Pitt B., White H., Nicolau J., et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. JAm Coll Cardiol 2005, 46:425-431.
46. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869.
47. Lang C.C., Struthers A.D. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol 2013, 10:125-134.
48. Fonarow G.C., Stough W.G., Abraham W.T., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. JAm Coll Cardiol 2007, 50:768-777.
49. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. NEngl J Med 2008, 359:2456-2467.
50. Mottram P.M., Haluska B., Leano R., et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004, 110:558-565.
51. Edelmann F., Wachter R., Schmidt A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013, 309:781-791.
52. Patel K., Fonarow G.C., Kitzman D.W., et al. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. JACC Heart Fail 2013, 1:40-47.
53. Treatment of preserved cardiac function heart failure with an Aldosterone anTagonist (TOPCAT) [online]. Available at:. Accessed November 30, 2011. http://www.topcatstudy.com/index.asp.
54. Hernandez A.F., Hammill B.G., O'Connor C.M., et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. JAm Coll Cardiol 2009, 53:184-192.
55. Bergstrom A., Andersson B., Edner M., et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004, 6:453-461.
56. Capomolla S., Febo O., Gnemmi M., et al. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J 2000, 139:596-608.
57. Metra M., Zacà V., Parati G., et al. Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. JCardiovasc Med (Hagerstown) 2011, 12:76-84.
58. Braunstein J.B., Anderson G.F., Gerstenblith G., et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. JAm Coll Cardiol 2003, 42:1226-1233.
59. Lenzen M.J., Scholte O.P., Reimer W.J., et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004, 25:1214-1220.
60. Brouwers F.P., Hillege H.L., van Gilst W.H., et al. Comparing new onset heart failure with reduced ejection fraction and new onset heart failure with preserved ejection fraction: an epidemiologic perspective. Curr Heart Fail Rep 2012, 9:363-368.
61. Adams K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005, 149:209-216.
62. Kalantar-Zadeh K., Block G., Horwich T., et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. JAm Coll Cardiol 2004, 43:1439-1444.
63. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. JAm Coll Cardiol 2009, 53:e1-e90.
64. Díez J., Frohlich E.D. Atranslational approach to hypertensive heart disease. Hypertension 2010, 55:1-8.